{"url":"https://lda.senate.gov/api/v1/filings/fb3c856e-64a5-4117-81a3-e643266b2d7a/","filing_uuid":"fb3c856e-64a5-4117-81a3-e643266b2d7a","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.senate.gov/filings/public/filing/fb3c856e-64a5-4117-81a3-e643266b2d7a/print/","filing_document_content_type":"text/html","income":"20000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"J. Caroline DeBerry","dt_posted":"2026-04-20T11:29:53-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"3711 Jenny Lynne Ln","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Fairfax","registrant_state":"VA","registrant_zip":"22030","registrant":{"id":401107856,"url":"https://lda.senate.gov/api/v1/registrants/401107856/","house_registrant_id":56203,"name":"TENAGRITY SOLUTIONS, LLC","description":null,"address_1":"3711 Jenny Lynne Ln","address_2":null,"address_3":null,"address_4":null,"city":"Fairfax","state":"VA","state_display":"Virginia","zip":"22030","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"CAROLINE DEBERRY","contact_telephone":"+1 202-494-9989","dt_updated":"2026-07-24T15:14:00.076226-04:00"},"client":{"id":60893,"url":"https://lda.senate.gov/api/v1/clients/60893/","client_id":60893,"name":"CENTER FOR ADDICTION SCIENCE, POLICY, AND RESEARCH","general_description":"Nonprofit focused on opportunities in policy and practice that can reduce addiction harms","client_government_entity":null,"client_self_select":false,"state":"RI","state_display":"Rhode Island","country":"US","country_display":"United States of America","ppb_state":"RI","ppb_state_display":"Rhode Island","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2024-07-19"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Discussions with / outreach to (and/or preparation for such outreach) Congressional offices and HHS officials re: potential avenues to increase GLP-1 access as a method of substance use disorder (SUD) treatment and other potential strategies for increasing innovation and the development of improved addiction medicines; FDA reforms including modernized endpoints for SUD; potential legislation to create a SUD PRV to increase development of and access to new SUD medicines; support for the FDA Commissioners national PRV and related pathways; support for NIH high-impact clinical trials evaluating repuposed off-patent therapeutics and widely used supplements with potential CMMI involvement; support for White House and CMMI exploration of non-opioid acute pain therapeutics. Related language requests in FY27 L-HHS and Ag-FDA appropriations.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":145280,"prefix":"ms","prefix_display":"MS.","first_name":"JENNY","nickname":null,"middle_name":"CAROLINE","last_name":"DEBERRY","suffix":null,"suffix_display":null},"covered_position":"Senior Legislative Assistant/ Legislative Assistant, Congressman John J. Duncan, Jr.; Senior Campaign Finance Analyst/ Campaign Finance Analyst, Federal Election Commission","new":false}],"government_entities":[{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"ALC","general_issue_code_display":"Alcohol and Drug Abuse","description":"Discussions with / outreach to (and/or preparation for such outreach) Congressional offices and HHS officials re: potential avenues to increase GLP-1 access as a method of substance use disorder (SUD) treatment and other potential strategies for increasing innovation and the development of improved addiction medicines; FDA reforms including modernized endpoints for SUD; potential legislation to create a SUD PRV to increase development of and access to new SUD medicines; support for the FDA Commissioners national PRV and related pathways; support for NIH high-impact clinical trials evaluating repuposed off-patent therapeutics and widely used supplements with potential CMMI involvement; support for White House and CMMI exploration of non-opioid acute pain therapeutics. Related language requests in FY27 L-HHS and Ag-FDA appropriations.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":145280,"prefix":"ms","prefix_display":"MS.","first_name":"JENNY","nickname":null,"middle_name":"CAROLINE","last_name":"DEBERRY","suffix":null,"suffix_display":null},"covered_position":"Senior Legislative Assistant/ Legislative Assistant, Congressman John J. Duncan, Jr.; Senior Campaign Finance Analyst/ Campaign Finance Analyst, Federal Election Commission","new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Discussions with / outreach to (and/or preparation for such outreach) Congressional offices and HHS officials re: potential avenues to increase GLP-1 access as a method of substance use disorder (SUD) treatment and other potential strategies for increasing innovation and the development of improved addiction medicines; FDA reforms including modernized endpoints for SUD; potential legislation to create a SUD PRV to increase development of and access to new SUD medicines; support for the FDA Commissioners national PRV and related pathways; support for NIH high-impact clinical trials evaluating repuposed off-patent therapeutics and widely used supplements with potential CMMI involvement; support for White House and CMMI exploration of non-opioid acute pain therapeutics. Related language requests in FY27 L-HHS and Ag-FDA appropriations.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":145280,"prefix":"ms","prefix_display":"MS.","first_name":"JENNY","nickname":null,"middle_name":"CAROLINE","last_name":"DEBERRY","suffix":null,"suffix_display":null},"covered_position":"Senior Legislative Assistant/ Legislative Assistant, Congressman John J. Duncan, Jr.; Senior Campaign Finance Analyst/ Campaign Finance Analyst, Federal Election Commission","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"CDT","general_issue_code_display":"Commodities (big ticket)","description":"Support for HR7840 (Event Contract Enforcement Act) addressing event contracts on war, etc. (recognizing such activity as gambling, a common addictive activity).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":145280,"prefix":"ms","prefix_display":"MS.","first_name":"JENNY","nickname":null,"middle_name":"CAROLINE","last_name":"DEBERRY","suffix":null,"suffix_display":null},"covered_position":"Senior Legislative Assistant/ Legislative Assistant, Congressman John J. Duncan, Jr.; Senior Campaign Finance Analyst/ Campaign Finance Analyst, Federal Election Commission","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"GAM","general_issue_code_display":"Gaming/Gambling/Casino","description":"Support for HR7840 (Event Contract Enforcement Act) addressing event contracts on war, etc. (recognizing such activity as gambling, a common addictive activity).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":145280,"prefix":"ms","prefix_display":"MS.","first_name":"JENNY","nickname":null,"middle_name":"CAROLINE","last_name":"DEBERRY","suffix":null,"suffix_display":null},"covered_position":"Senior Legislative Assistant/ Legislative Assistant, Congressman John J. Duncan, Jr.; Senior Campaign Finance Analyst/ Campaign Finance Analyst, Federal Election Commission","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}